Initially, PD-L1 expression in the tumor environment seemed to be positively correlated with response to PD-1/PD-L1-blocking antibodies, but several exceptions have led to the recognition of PD-L1 as an imperfect marker. This evidence concerns the gene PDCD1 and neoplasm.